CTRI/2024/04/065084
Recruiting
Phase 3
A multicentric, randomized, prospective, double blind, parallel group, comparative, active controlled, phase III clinical study to evaluate the efficacy, safety and tolerability of Fixed Dose Combination of Dapagliflozin 10 mg and Telmisartan 80 mg versus concurrent use Dapagliflozin 10mg tablets and Telmisartan 80mg tablets in patients with Chronic Kidney Disease. - NI
ERIS LIFESCIENCES LIMITED0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecified
- Sponsor
- ERIS LIFESCIENCES LIMITED
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Willing to give consent to participate
- •2\. Female or male aged 18\-65 (both inclusive) years at the time of consent.
- •3\. Women of childbearing potential who comply to use an adequate method of contraception to avoid pregnancy throughout the study \& who have a negative urine pregnancy test.
- •4\. UACR more than 200 and less than 5000 mg/g at visit 1\.
- •5\. eGFR greater than 25 and less than 75 mL/min/1\.73m2 (CKD\-EPI Formula) at visit 1\.
- •6\. Stable, and patient with maximum tolerated labelled daily dose, treatment with ACE\-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated.
Exclusion Criteria
- •1\. Polycystic kidney disease, lupus nephritis or ANCA associated vasculitis.
- •2\. Receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment.
- •3\. History of organ transplantation.
- •4\. Type 1 diabetes mellitus (T1D).
- •5\. New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment.
- •6\. MI, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.
- •7\. Coronary revascularization (percutaneous coronary intervention PCI or coronary artery bypass grafting CABG) or valvular repair/replacement within 12 weeks prior to enrolment or is planned to undergo any of these procedures after randomization.
- •8\. Any condition outside the renal and CV disease area, such as but not limited to malignancy, with a life expectancy of less than 2 years based on investigators clinical judgement.
- •9\. Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma).
- •10\. Hepatic impairment (aspartate transaminase AST or alanine transaminase ALT more than 3x the upper limit of normal ULN, or total bilirubin more than 2x ULN at time of enrolment).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
PMZ-1620 for the treatment of stroke.Health Condition 1: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteriesCTRI/2019/09/021373Pharmazz India Private Limited158
Recruiting
Phase 4
sovateltide Injection for the treatment of acute cerebral ischemic strokeHealth Condition 1: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteriesCTRI/2023/12/060404Pharmazz India Private Limited
Completed
Phase 3
A clinical trial to study the safety and efficacy of 2mg and 4mg of ZYH1 compared to placebo in hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VI)].Health Condition 1: E785- Hyperlipidemia, unspecifiedHealth Condition 2: null- In hypertriglyceridemia with type II diabetes not controlled with Atorvastatin therapy.CTRI/2009/091/000533Cadila Healthcare Limited300
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy and safety of Lower Back Comfort in patients with Lower Back AcheHealth Condition 1: null- Lower Back AcheCTRI/2018/03/012822Sami Labs Limited
Completed
Phase 2
To Study the effect of PMZ-1620 in stroke patients.Health Condition 1: null- Acute Ischemic StrokeHealth Condition 2: I635- Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteriesCTRI/2017/11/010654Pharmazz India Private Limited40